CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
donepezil hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01466270
NCT01466270Phase 2Completed
CompareCT.gov

A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy

Wake Forest University Health Sciences·interventional·Posted Nov 7, 2011·Updated Oct 20, 2021

In Brief

A Phase 2 clinical trial evaluating donepezil hydrochloride and Placebo for Anxiety Disorder and 5 related conditions. Completed, enrolled 62 participants.

Detailed Summary

RATIONALE: Donepezil hydrochloride may help lessen cognitive dysfunction caused by chemotherapy. PURPOSE: This phase II trial is studying donepezil hydrochloride in treating cognitive dysfunction after chemotherapy in female breast cancer survivors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorder, Breast Cancer, Cognition Disorders, Depression, Fatigue, Sleep Disorders
Countries--
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2011
Enrollment StartJul 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.7 years ago

Interventions

donepezil hydrochloridedrug

Given PO

Placebodrug

Given PO